Short-Course Ruxolitinib Initiated at Neutrophil Engraftment for Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter, Randomized, Open-Label, Controlled Phase II Trial.
文献摘要
Acute graft-versus-host disease (aGVHD) remains a leading cause of non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). On the cyclosporine A (CsA)/methotrexate (MTX)/mycophenolate mofetil (MMF) backbone, MMF withdrawal around engraftment creates an immunosuppression gap coinciding with peak peri-engraftment alloreactivity. To test whether a 14-day ruxolitinib course initiated at confirmed neutrophil engraftment, within a donor-stratified MMF discontinuation schedule, reduces the 100-day cumulative incidence of grade II to IV aGVHD versus standard prophylaxis alone. Multicenter, randomized, open-label, phase II superiority trial (ChiCTR1900027971) at 5 transplant centers in North China (December 2019 to August 2022). A total of 171 patients (aged 12 to 66 years) with hematologic malignancies or severe aplastic anemia (SAA) were randomly assigned 1:1 to ruxolitinib plus standard prophylaxis (n=86) or standard prophylaxis alone (n=85). MMF was discontinued per a donor-stratified schedule: full withdrawal at engraftment for matched sibling recipients; half-dose at engraftment, discontinuation by day +30 for matched unrelated and haploidentical recipients. Ruxolitinib (5 mg twice daily for 7 days, then 5 mg once daily for 7 days; total 105 mg) was started at confirmed neutrophil engraftment. The primary endpoint was the 100-day cumulative incidence of grade II to IV aGVHD, with death without prior aGVHD as a competing event (Fine-Gray model). Data cutoff: December 31, 2023. The 100-day cumulative incidence of grade II to IV aGVHD was 14.0% (12/86) versus 34.1% (29/85) (subdistribution hazard ratio [sHR] 0.35, 95% confidence interval [CI] 0.18 to 0.68; P = .002), an absolute reduction of 20.1% (number needed to treat [NNT] 5.0, 95% CI: 3.1 to 13.0). Grade III to IV aGVHD was 7.0% versus 16.5% (sHR 0.37, 95% CI: 0.14 to 0.98; P = .047). All 85 treated patients completed the 14-day course without dose modification; grade ≥3 adverse events within 100 days were similar between arms. Pre-transplant measurable residual disease (MRD) positivity was unbalanced between arms (63.5% versus 45.9%; P = .032), potentially confounding survival comparisons. Two-year overall survival (OS) was 81.4% versus 82.4% (HR 0.89, 95% CI: 0.45 to 1.75; P = .674). Among 150 patients with hematologic malignancies, 2-year NRM was 8.1% versus 11.8% (sHR 0.63, 95% CI: 0.26 to 1.53; P = .308), relapse 16.2% versus 11.8% (sHR 1.11, 95% CI: 0.53 to 2.32; P = .782; MRD-adjusted sHR 0.95, 95% CI: 0.44 to 2.06), disease-free survival 75.7% versus 76.3% (HR 0.92, 95% CI: 0.48 to 1.76; P = .834), and GVHD-free, relapse-free survival 64.9% versus 56.6% (HR 0.76, 95% CI: 0.47 to 1.23; P = .247). The aGVHD benefit was consistent across all prespecified subgroups (all P for interaction >.10). Short-course ruxolitinib initiated at neutrophil engraftment reduced grade II to IV aGVHD by 20.1% (NNT 5.0), with an acceptable safety profile and no evidence of impaired graft-versus-leukemia effect after MRD balancing. Survival endpoints may be confounded by the MRD imbalance, steroid-refractory aGVHD crossover, and relapse predominance. MRD-stratified phase III trials are warranted.